Shanghai Orsin Medical Technology Co., Ltd.
Focus on life and pursue excellence
Add to Cart
1. Product Description
Orsin Medical Technology’s Cell-Free DNA (cf DNA) Collection Tube is a state-of-the-art solution designed for the efficient stabilization, preservation, and transport of circulating cell-free DNA in blood samples. Utilizing advanced stabilizing reagents, our tubes ensure the integrity of cfDNA for up to 14 days at room temperature, minimizing degradation and contamination risks.
✔ High Stability – Proprietary formula inhibits nucleic acid degradation, preserving sample quality.
✔ Room-Temperature Storage – Eliminates the need for immediate freezing, reducing logistical costs.
✔ Wide Compatibility – Suitable for downstream applications, including NGS, PCR, and liquid biopsy.
✔ Clinical-Grade Reliability – Manufactured under strict ISO standards for consistent performance.
Ideal for cancer research, prenatal testing, and transplant monitoring, Orsin’s cfDNA tubes streamline sample handling while ensuring accurate, reproducible results.
2. Specification
| Parameter | Description/Options |
|---|---|
| Tube Cap Color | Red, Lavender (Purple), Green, Gray, Blue, Yellow, Black, etc. |
| Additive Type | None (Clot activator), EDTA, Heparin, Sodium Citrate, Sodium Fluoride, etc. |
| Clinical Use | Serum separation, Hematology, Coagulation, Chemistry, Glucose, Blood Bank, etc. |
| Nominal Volume | 2ml, 3ml, 4ml, 5ml, 6ml, 7ml, 8ml, 10ml, etc. |
| Draw Volume Range | ±10% of nominal volume (e.g., 4.5-5.5ml for 5ml tube) |
| Tube Diameter | 13mm, 16mm (standard adult size) |
| Tube Length | 75mm, 100mm, etc. |
| Material | PET plastic, Glass |
| Sterilization | Gamma irradiation, EO Gas |
| Expiry Period | Typically 12-36 months (from date of manufacture) |
| Hemolysis Rate | ≤0.1% (for most chemistry tubes) |
| Clotting Time | 30 mins (for serum tubes with clot activator) |
| Centrifuge Speed | 1300-2200g (tube material dependent) |
| Safety Features | Hemogard™ closure, BD-PTS, Needle protection system |
| Certifications | ISO 6710, CE Marked, FDA 510(k) |
Common Parameters by Tube Color (Example):
| Cap Color | Additive | Mixing | Inversion Count | Clinical Applications |
|---|---|---|---|---|
| Red | None/Clot activator | 5× | 5-6 | Serum chemistry, Immunology |
| Lavender | K2/K3 EDTA | 8-10× | 8-10 | Hematology (CBC, Blood Smear) |
| Green | Lithium Heparin | 8-10× | 8-10 | Plasma chemistry, STAT tests |
| Gray | NaF/K Oxalate | 8-10× | 8-10 | Glucose tolerance, Alcohol tests |
| Blue | Sodium Citrate | 3-4× | 3-4 | Coagulation tests (PT, APTT) |
| Application | Sensitivity | Specificity | PPV | NPV | LoD |
|---|---|---|---|---|---|
| NIPT T21 | >99% | >99.9% | >90% | >99.9% | 2-4% FF |
| ctDNA MRD | 0.01% VAF | 95-99% | 80% | 98% | 0.1% MAF |
| dd-cfDNA | 85-92% | 78-85% | 75% | 90% | 0.5% |
3 . Application
1.Precision Oncology Solutions
Unparalleled sensitivity for early detection
Serial monitoring capability for dynamic conditions
Comprehensive genomic coverage
Streamlined workflow integration
CLIA-certified analytical validity
Novel biomarker discovery pipelines
Clinical trial enrichment strategies
Pharmacodynamic endpoint development
Therapeutic target identification
2.Research and Development Applications Biomedical Innovation
Cardiovascular event risk stratification
Neurodegenerative disease progression tracking
Autoimmune disorder monitoring
Metabolic disease assessment
3.Chronic Disease Management
Rapid sepsis pathogen identification
Culture-resistant infection diagnosis
Antimicrobial resistance profiling
Viral load monitoring
4.Cutting-Edge Diagnostic Applications Next-Generation Infection Detection
Real-time graft rejection monitoring via donor-derived DNA
Quantitative assessment of transplant engraftment success
Early detection of post-transplant complications
Personalized immunosuppression adjustment
5.Transplant Medicine Advancements
Safe, accurate fetal chromosomal abnormality screening
Comprehensive genetic risk assessment from maternal circulation
Early prediction of pregnancy-related complications
Non-invasive fetal RhD status determination
6.Advanced Prenatal Care
Early-stage tumor detection through ultra-sensitive ctDNA profiling
Dynamic monitoring of therapeutic efficacy and emerging resistance
Comprehensive metastatic assessment without invasive procedures
Personalized treatment selection through longitudinal mutation tracking